Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekhon, Sahil, Jeon, Caleb, Nakamura, Mio, Yan, Di, Afifi, Ladan, Bhutani, Tina, Levin, Ethan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774608/
https://www.ncbi.nlm.nih.gov/pubmed/29387609
http://dx.doi.org/10.2147/PTT.S129792
_version_ 1783293781729083392
author Sekhon, Sahil
Jeon, Caleb
Nakamura, Mio
Yan, Di
Afifi, Ladan
Bhutani, Tina
Levin, Ethan
author_facet Sekhon, Sahil
Jeon, Caleb
Nakamura, Mio
Yan, Di
Afifi, Ladan
Bhutani, Tina
Levin, Ethan
author_sort Sekhon, Sahil
collection PubMed
description Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate–severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.
format Online
Article
Text
id pubmed-5774608
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57746082018-01-31 Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis Sekhon, Sahil Jeon, Caleb Nakamura, Mio Yan, Di Afifi, Ladan Bhutani, Tina Levin, Ethan Psoriasis (Auckl) Review Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate–severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab. Dove Medical Press 2017-11-16 /pmc/articles/PMC5774608/ /pubmed/29387609 http://dx.doi.org/10.2147/PTT.S129792 Text en © 2017 Sekhon et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Sekhon, Sahil
Jeon, Caleb
Nakamura, Mio
Yan, Di
Afifi, Ladan
Bhutani, Tina
Levin, Ethan
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_full Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_fullStr Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_full_unstemmed Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_short Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
title_sort clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774608/
https://www.ncbi.nlm.nih.gov/pubmed/29387609
http://dx.doi.org/10.2147/PTT.S129792
work_keys_str_mv AT sekhonsahil clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis
AT jeoncaleb clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis
AT nakamuramio clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis
AT yandi clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis
AT afifiladan clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis
AT bhutanitina clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis
AT levinethan clinicalutilityofixekizumabinthetreatmentofmoderatetosevereplaquepsoriasis

Ejemplares similares